Contents
pdf Download PDF
pdf Download XML
58 Views
13 Downloads
Share this article
Research Article | Volume 12 Issue 11 (November, 2026) | Pages 309 - 316
Clinical and Hematological Spectrum of Hemoglobinopathies and Thalassemias Detected by High-Performance Liquid Chromatography: A Three-Year Retrospective Study at a Tertiary Care Centre in Southern Assam
 ,
 ,
 ,
1
Assistant Professor, Department of Pathology, Silchar Medical College and Hospital, Silchar, Assam, India.
2
Assistant Professor, Department of Pathology, Maharshi Devraha Baba Autonomous State Medical College, Deoria, Uttar Pradesh, India.
3
Professor and Head, Department of Pathology, Silchar Medical College and Hospital, Silchar, Assam, India.
Under a Creative Commons license
Open Access
Received
Sept. 5, 2026
Revised
Oct. 10, 2026
Accepted
Oct. 21, 2026
Published
Nov. 16, 2026
Abstract
Background: Hemoglobin E (HbE), β-thalassemia, and sickle hemoglobin disorders show marked geographic heterogeneity in India. Southern Assam lies within a region where HbE-associated conditions are clinically important, and laboratory characterization has implications for carrier identification and genetic counseling. Objective: To characterize the diagnostic distribution, demographic profile, hematological indices, and available clinical manifestations of hemoglobinopathies and thalassemias identified through high-performance liquid chromatography (HPLC) at a tertiary-care centre in Southern Assam. Materials and Methods: A retrospective, record-based study examined HPLC reports, complete blood count data, and clinical records in the Department of Pathology, Silchar Medical College and Hospital, from June 2023 to June 2026. A total of 505 hemoglobinopathy cases were included after applying the eligibility criteria. Diagnostic categories, demographic characteristics, hematological indices, and clinical manifestations were analyzed using descriptive statistics, Pearson's chi-square tests, and one-way analysis of variance. Results: Of 816 HPLC records screened, 536 showed a potentially abnormal or relevant hemoglobin pattern; 505 records remained after exclusions. The commonest pattern was HbE trait (192/505, 38.0%), followed by β-thalassemia trait (88/505, 17.4%) and homozygous HbE disease (76/505, 15.0%). HbE-related categories accounted for 334/505 (66.1%). Mean hemoglobin was 11.4 ± 1.2 g/dL in HbE trait and 8.6 ± 1.6 g/dL in HbE/β-thalassemia (four-group ANOVA P < 0.001). Conclusion: HbE-related hemoglobinopathies predominated in this tertiary-care series, while HbE/β-thalassemia and severe thalassemia phenotypes showed lower hemoglobin concentrations and greater clinical burden than uncomplicated carrier states. The findings emphasize the value of integrated HPLC, hematological assessment, clinical correlation, and genetic counseling.
Keywords
INTRODUCTION
Inherited hemoglobin disorders represent a major group of monogenic conditions that affect the structure or synthesis of globin chains. Structural variants such as hemoglobin E (HbE) and hemoglobin S (HbS) alter the amino-acid sequence of globin chains, whereas thalassemias result from reduced or absent synthesis of one or more globin chains. Clinical manifestations range from asymptomatic carrier states to severe, transfusion-dependent anemia, with important consequences for survival, healthcare use, and reproductive counseling [1–4]. India has a heterogeneous distribution of hemoglobin disorders, reflecting geographic, ancestral, and population-level differences in carrier frequencies. Northeast India is particularly associated with HbE, an abnormal β-globin variant that can produce a mild phenotype in heterozygous carriers but may cause significant disease when inherited with a β-thalassemia allele. HbE/β-thalassemia has a broad clinical spectrum, and phenotypic severity cannot be inferred from hemoglobin fractions alone [3,5]. Sickle cell disorders and other compound heterozygous states add complexity to the regional diagnostic landscape [5,6]. High-performance liquid chromatography separates hemoglobin fractions and estimates the proportions of HbA, HbA₂, HbF, and common variants. It is a widely used first-line technique, particularly when combined with complete blood count (CBC) parameters, peripheral blood morphology, family history, and clinical assessment. Nevertheless, the resulting chromatographic pattern is often presumptive: iron deficiency, recent transfusion, increased HbF, age-related physiological variation, or co-eluting variants may complicate interpretation. Confirmatory testing is essential when fractions or clinical features are atypical [7–10]. Hospital-based case series provide information on which hemoglobinopathies are encountered in routine care, although their diagnostic proportions should not be interpreted as population prevalence. An Upper Assam study reported a substantial proportion of HbE disorders among patients referred for HPLC testing [5]. An earlier pediatric series from Southern Assam also described multiple HbE-, HbS-, and β-thalassemia-related patterns in children evaluated for microcytic hypochromic anemia [11]. However, the age-inclusive spectrum among records from the subsequent three-year period at Silchar Medical College and Hospital remains to be characterized. The study aimed to describe the distribution of hemoglobinopathy categories diagnosed between June 2023 and June 2026 and to examine their demographic, hematological, and clinical profiles. The findings have implications for regional diagnostic pathways, carrier identification, and genetic counseling, while recognizing the referral-based nature of the patient population.
MATERIALS AND METHODS
2.1 Study design, setting, and period A retrospective, descriptive, record-based study was undertaken in the Department of Pathology, Silchar Medical College and Hospital, Silchar, Assam, India. Laboratory and clinical records spanning June 2023 to June 2026 were examined. The study population included patients evaluated for suspected or established hemoglobinopathy or thalassemia. The analysis characterized the institutional diagnostic case mix rather than population prevalence, in accordance with relevant STROBE reporting principles [12]. 2.2 Data sources and case ascertainment The data sources comprised hematology laboratory registers, hemoglobinopathy screening records, HPLC chromatogram reports, complete blood count (CBC) reports, and relevant hospital case records. Patient age, sex, clinical features, final hemoglobinopathy classification, hematological indices, and hemoglobin fractions were extracted into a standardized de-identified data sheet. Records belonging to the same patient were reconciled, and only the first qualifying diagnostic episode was included in the primary distribution analysis. Repeat investigations contributed to diagnostic interpretation but were not counted as additional patients. 2.3 Eligibility criteria Eligible cases included patients of either sex and any age with a final laboratory diagnosis of hemoglobinopathy or thalassemia between June 2023 and June 2026 and sufficient documentation of age, sex, and diagnostic classification. Cases with partial CBC or clinical documentation were included in analyses of the variables available for that patient, with variable-specific denominators used where required. Records were excluded if they were illegible or materially incomplete, represented duplicate patient entries, reflected a red-cell transfusion in the preceding three months, yielded an inconclusive hemoglobin pattern, or lacked adequate evidence for a diagnostic classification. The main denominator was the number of eligible, unique patients with a classified hemoglobinopathy. Records excluded for recent transfusion and other reasons were counted separately. 2.4 Hematological examination and HPLC interpretation Hematological findings were obtained from automated CBC reports, including hemoglobin concentration (Hb), red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW). Available peripheral blood smear reports were reviewed for microcytosis, hypochromia, anisopoikilocytosis, target cells, nucleated erythrocytes, and other relevant abnormalities. Age, transfusion history, and evidence of possible iron deficiency were considered when interpreting hematological patterns. Hemoglobin fractions were assessed using routine high-performance liquid chromatography (HPLC) reports. HbA, HbA₂, HbF, and variant fractions were recorded as percentages, and chromatographic patterns were interpreted alongside the CBC findings and clinical information. HPLC was the principal hemoglobin fractionation method. As HbE may elute in the HbA₂/E window on certain cation-exchange systems, the combined HbA₂/E fraction was not interpreted as a separately quantified HbA₂ concentration. Unusual HbS, HbD, or other variant patterns were evaluated in relation to available corroborating evidence [7–10]. Each case was classified according to the final laboratory and clinical diagnosis. β-Thalassemia major/intermedia was classified according to the documented diagnostic phenotype rather than hemoglobin fractions alone. Compound conditions, including HbE/β-thalassemia and HbS/β-thalassemia, were categorized using the combined laboratory pattern, hematological indices, and available clinical assessment. 2.5 Diagnostic categories and outcomes Diagnostic categories included HbE trait, homozygous HbE disease, HbE/β-thalassemia, β-thalassemia trait, β-thalassemia major/intermedia, sickle cell trait, sickle cell disease, HbS/β-thalassemia, and other mixed or uncommon hemoglobinopathies. The primary outcome was the distribution of diagnostic categories among eligible patients. Secondary outcomes included age, sex, hemoglobin concentration, red-cell indices, HbF and HbA₂ or variant fractions, and recorded clinical manifestations. Clinical-feature proportions were calculated using records with an assessment documented for the respective feature. 2.6 Statistical analysis Statistical analyses were performed using IBM SPSS Statistics version 26. Categorical variables were summarized as frequencies and percentages, and continuous variables as mean ± standard deviation. Differences in diagnostic distributions by age group and sex were evaluated using Pearson's chi-square test. Hemoglobin concentrations in four prespecified diagnostic groupings were compared using one-way analysis of variance. All tests were two-sided, and P < 0.05 was considered statistically significant. Missing observations were excluded from analyses of the corresponding variable, and clinical-feature percentages were calculated using the number of assessed records as the denominator. 2.7 Ethical considerations The study was designed as a retrospective review of existing laboratory and hospital records, without direct patient contact, additional sample collection, or study-specific intervention. De-identification was incorporated into the data abstraction process, and the protocol included a request for waiver of individual informed consent in view of the minimal risk associated with secondary record review.
RESULTS
A total of 816 HPLC records were screened during June 2023–June 2026. An abnormal or potentially significant hemoglobin pattern was recorded in 536 reports. After excluding 17 records with recent transfusion and 14 duplicate, incomplete or inconclusive records, 505 patients were included. There were 247 males (48.9%) and 258 females (51.1%); mean age was 23.2 ± 13.7 years. Table 1 summarizes the case identification and demographic characteristics. Table 1. Study cohort identification and demographic profile Characteristic Result Total HPLC records screened 816 Records with abnormal/relevant HPLC patterns 536 Excluded: recent blood transfusion (≤3 months) 17 Excluded: duplicate, inconclusive or inadequate records 14 Final analyzed patients 505 Male, n (%) 247 (48.9%) Female, n (%) 258 (51.1%) Age, years: mean ± SD or median (IQR) 23.2 ± 13.7 Age 0–17 / 18–39 / 40–59 / ≥60 years, n (%) 191 (37.8%)/251 (49.7%)/59 (11.7%)/4 (0.8%) The largest age group was 18–39 years (251/505, 49.7%), followed by children and adolescents aged 0–17 years (191/505, 37.8%). Adults aged 40–59 years accounted for 59 cases, while 4 were aged 60 years or older. Age-band distributions varied by diagnosis (Pearson χ² = 93.7, P < 0.001). Table 2. Distribution of hemoglobinopathy and thalassemia categories Diagnostic category n % of diagnosed cases HbE trait 192 38.0 Homozygous HbE disease 76 15.0 HbE/β-thalassemia 66 13.1 β-thalassemia trait 88 17.4 β-thalassemia major/intermedia 36 7.1 Sickle cell trait 22 4.4 Sickle cell disease 11 2.2 HbS/β-thalassemia 9 1.8 Other mixed/rare patterns 5 1.0 Total 505 100.0 HbE-related diagnoses accounted for 334 cases (66.1%), consisting of HbE trait, homozygous HbE and HbE/β-thalassemia. β-thalassemia without HbE or HbS accounted for 124 cases (24.6%), and sickle hemoglobin disorders accounted for 42 (8.3%). Other rare or mixed patterns accounted for 5 cases. The diagnostic category distribution is presented in Table 2 and Figure 1. The sex distribution did not show strong evidence of a difference across the nine diagnostic categories (χ² = 7.3, P = 0.509). Table 3. Hematological and HPLC profile by diagnostic category Measure HbE trait HbE/β-thal. β-thal. trait HbS disorders Number with CBC data 182 60 84 37 Hemoglobin (g/dL) 11.4 ± 1.2 8.6 ± 1.6 10.7 ± 1.6 10.9 ± 1.8 RBC count (×10¹²/L) 4.7 ± 0.5 4.1 ± 0.6 5.3 ± 0.6 4.2 ± 0.7 MCV (fL) 74.0 ± 6.1 65.7 ± 5.9 66.4 ± 4.9 77.2 ± 9.4 MCH (pg) 23.8 ± 2.1 20.4 ± 2.1 21.2 ± 2.1 25.2 ± 3.3 MCHC (g/dL) 31.8 ± 0.9 30.9 ± 1.3 31.5 ± 1.0 31.7 ± 1.6 RDW (%) 15.1 ± 1.6 20.1 ± 2.3 15.9 ± 1.9 17.2 ± 3.3 HbF (%) 1.6 ± 0.9 21.5 ± 8.4 1.7 ± 0.8 7.4 ± 7.0 HbA₂ or reported HbA₂/E fraction (%) 27.6 ± 3.6 51.3 ± 8.5 5.3 ± 0.7 3.4 ± 0.9 Hematological profiles varied substantially across diagnostic groups (Table 3). Mean hemoglobin was 11.4 ± 1.2 g/dL in HbE trait, 8.6 ± 1.6 g/dL in HbE/β-thalassemia, 10.7 ± 1.6 g/dL in β-thalassemia trait and 10.9 ± 1.8 g/dL in the combined sickle-disorder group. One-way ANOVA indicated a difference in mean hemoglobin across these four groupings (F = 55.26, P < 0.001). Red-cell indices showed marked microcytosis among β-thalassemia and HbE/β-thalassemia categories; Figure 2 summarizes the hemoglobin distributions. Chromatographic fractions were interpreted according to the HPLC pattern, recognizing that HbE may co-elute in the HbA₂/E window. Table 4. Clinical features and available documentation Clinical variable Assessed (n) Present (n) Present (%) Pallor 442 240 54.3 Fatigue or weakness 449 200 44.5 Jaundice 379 60 15.8 Splenomegaly 365 69 18.9 Hepatomegaly 380 33 8.7 History of transfusion dependence 364 52 14.3 Family history of hemoglobinopathy 376 112 29.8 Other relevant complications 350 53 15.1 Among records with a documented clinical assessment, pallor was present in 240/442 (54.3%) and fatigue or weakness in 200/449 (44.5%). A history of transfusion dependence was recorded in 52/364 (14.3%). Other documented manifestations are summarized in Table 4. Clinical-feature denominators differ because assessments were not uniformly documented. Table 5. Hemoglobinopathy spectrum in a published Southern Assam pediatric series (June 2021–May 2022) Hemoglobinopathy pattern Published cases (n) % among 69 abnormal cases HbE trait 17 24.63 Homozygous HbE 8 11.59 β-thalassemia trait 14 20.28 β-thalassemia major 9 13.04 HbE/β-thalassemia 6 8.69 Sickle cell trait 10 14.49 Sickle cell disease 4 5.79 HbS/β-thalassemia 1 1.44 Total 69 100.00
DISCUSSION
The distribution of hemoglobin disorders in this tertiary-care series was dominated by HbE-related phenotypes (66.1%), with HbE trait (38.0%) the single most frequent category. This case mix is biologically and epidemiologically plausible in Southern Assam, which forms part of the wider HbE-associated region of northeastern India and Southeast Asia [2,3,5]. The proportions in a referral-based HPLC cohort reflect both local genetic background and clinical testing practices, and should not be interpreted as community prevalence. The distribution broadly parallels reports from Upper Assam, where HbE-associated patterns feature prominently among HPLC referrals [5]. In the present case mix, β-thalassemia trait and the clinically consequential HbE/β-thalassemia category also made substantial contributions. Differences among published series can arise from age structure, obstetric and pediatric referral streams, criteria for referral, and availability of screening; direct comparisons require consistent denominators. A previous study at a tertiary hospital of southern assam assessed 120 children with microcytic hypochromic anemia during June 2021–May 2022. Of these, 69 had abnormal hemoglobin patterns, including 17 with HbE trait, eight with homozygous HbE, 14 with β-thalassemia trait, nine with β-thalassemia major, six with HbE/β-thalassemia, 10 with sickle trait, four with sickle disease, and one with HbS/β-thalassemia [11]. The pediatric series provides an additional regional perspective on the range of hemoglobinopathy phenotypes detected in routine clinical practice. The pronounced hematological differences between uncomplicated carrier states and compound conditions are clinically relevant. Mean hemoglobin in HbE/β-thalassemia (8.6 ± 1.6 g/dL) was substantially lower than in HbE trait (11.4 ± 1.2 g/dL). This pattern is consistent with the heterogeneous anemia burden of HbE/β-thalassemia described by Fucharoen and Weatherall [3]. HbF proportions, red-cell size, clinical manifestations and transfusion history can refine severity assessment, although genotype remains important when the precise inheritance pattern is uncertain [3,4]. Low MCV and MCH were particularly evident in β-thalassemia trait and HbE/β-thalassemia, underscoring the value of combining red-cell indices with chromatographic findings. Carriers may present with persistent microcytosis despite only mild anemia, and the CBC pattern alone is not sufficient to separate thalassemia from iron deficiency. HbA₂ determination can support the diagnosis of β-thalassemia trait but requires cautious interpretation when HbE or other variants co-elute [7–10]. The distinction between HPLC and electrophoresis is also clinically relevant. HPLC offers reproducible quantitative fractionation, but retention time and peak assignment depend on the analytical platform and may include co-elution. The HbE peak typically appears in the HbA₂/E region on some commonly used cation-exchange systems; consequently, an apparently elevated fraction in this window should not be used as a direct substitute for separately quantified HbA₂. When the report and red-cell indices are discordant, review of the chromatogram, repeat testing after relevant clinical factors have resolved, capillary electrophoresis or another orthogonal method, and targeted molecular analysis may be appropriate [8–10]. Clinical records also need to distinguish heterozygous sickle trait from sickle cell disease or HbS/β-thalassemia, because downstream implications differ substantially. Fractionation results may be influenced by recent transfusion, which explains the protocol’s three-month exclusion criterion. In infants, age-related HbF predominance introduces another interpretative challenge. For uncommon patterns, diagnostic labels should follow the confidence supported by the original laboratory record rather than relying on a numerical cutoff that may not apply across platforms. A diagnostic profile characterized by a large number of carrier and compound heterozygous states has practical implications for preconception counseling, antenatal screening, partner testing, and cascade screening of family members. People with HbE trait or β-thalassemia trait may be clinically well but still require accurate counseling on reproductive risks, while individuals with HbE/β-thalassemia or severe β-thalassemia phenotypes may need closer evaluation and coordinated specialist follow-up. Screening pathways should therefore emphasize interpretable laboratory reporting and access to genetic counseling [13]. The retrospective, single-centre design is susceptible to referral bias and may overrepresent symptomatic patients. Clinical features were documented inconsistently, and laboratory categories derived from HPLC may not correspond perfectly to molecular genotypes. Incomplete information on iron status, prior transfusion, family history and severity can further influence interpretation. As the denominator consists of patients referred for diagnostic testing, observed percentages describe the institutional case mix and cannot be generalized as population prevalence.
CONCLUSION
HbE-associated conditions formed the largest group of HPLC-classified hemoglobinopathies in the reported case mix, accounting for 66.1% of diagnoses, followed by isolated β-thalassemia and sickle hemoglobin disorders. Compound HbE/β-thalassemia and severe thalassemia phenotypes showed more pronounced anemia and clinical manifestations than common carrier states. Integration of HPLC with CBC parameters, clinical assessment, and confirmatory testing where indicated is essential for meaningful categorization and appropriate family counseling in Southern Assam.
REFERENCES
1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–487. doi:10.2471/BLT.06.036673. 2. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert Rev Hematol. 2010;3(1):103–117. doi:10.1586/ehm.09.74. 3. Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012;2(8):a011734. doi:10.1101/cshperspect.a011734. 4. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. doi:10.1186/1750-1172-5-11. 5. Baruah MK, Saikia M, Baruah A. Pattern of hemoglobinopathies and thalassemias in upper Assam region of North Eastern India: high performance liquid chromatography studies in 9000 patients. Indian J Pathol Microbiol. 2014;57(2):236–243. doi:10.4103/0377-4929.134680. 6. Sachdev R, Dam AR, Tyagi G. Detection of Hb variants and hemoglobinopathies in Indian population using HPLC: report of 2600 cases. Indian J Pathol Microbiol. 2010;53(1):57–62. doi:10.4103/0377-4929.59185. 7. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci. 2020;7:74. doi:10.3389/fmolb.2020.00074. 8. Bain BJ. Haemoglobinopathy diagnosis: algorithms, lessons and pitfalls. Blood Rev. 2011;25(5):205–213. doi:10.1016/j.blre.2011.04.001. 9. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol. 2013;35(5):465–479. doi:10.1111/ijlh.12037. 10. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–383. doi:10.1016/S0140-6736(11)60283-3. 11. Paul Choudhury A, Debnath A, Chaubey RN. A study of hemoglobinopathies in children with microcytic hypochromic anemia in southern part of Assam. Int J Dent Med Sci Res. 2025;7(2):252–265. doi:10.35629/6018-0702252265. 12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85(11):867–872. doi:10.2471/BLT.07.045120. 13. American College of Obstetricians and Gynecologists. Carrier screening for genetic conditions. Committee Opinion No. 691. Obstet Gynecol. 2017;129(3):e41–e55. Available at: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions. 14. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704–712. 15. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331–4336. doi:10.1182/blood-2010-01-251348.
Recommended Articles
Review Article
Accuracy of Artificial Intelligence vs. Human Clinicians in Predicting Dental Implant Success Rates in Compromised Bone Morphologies: A Systematic Review
...
Published: 17/11/2026
Research Article
Causes of recurrence after inguinal hernia repair, surgical factors, patients factors and strategies for prevention
...
Published: 30/09/2026
Research Article
Diabetic Ketoacidosis (DKA): Precipitating Factors, Management Gaps, and Outcomes at Ayub Teaching Hospital, Abbottabad: A Retrospective Observational Cohort Study
...
Published: 28/08/2026
Original Article
Comparative Study of Single-Bundle Versus Double-Bundle Arthroscopic Anterior Cruciate Ligament Reconstruction
...
Published: 28/04/2025
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice